Log in

NASDAQ:BXRXBaudax Bio Stock Price, Forecast & News

+0.16 (+3.67 %)
(As of 05/27/2020 04:00 PM ET)
Today's Range
Now: $4.52
50-Day Range
MA: $3.12
52-Week Range
Now: $4.52
Volume887,842 shs
Average Volume748,490 shs
Market Capitalization$79.41 million
P/E RatioN/A
Dividend YieldN/A
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. Its lead product candidate is intravenous form of meloxicam, a non-opioid that has completed Phase III clinical trials for the management of moderate to severe pain; and is in the Phase IIIb clinical trials in colorectal surgery and orthopedic surgery patients to assess opioid consumption, pain intensity, and length of hospital stay with associated pharmacoeconomic parameters. The company's early-stage product candidates includes RP1000, an intermediate-acting neuromuscular blocking agent (NMBA) that is in phase I clinical trial; and RP2000, an ultrashort-acting NMBA, which is in pre-clinical trial; and a reversal agent, as well as Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.23 out of 5 stars

Industry, Sector and Symbol

Industry Miscellaneous health & allied services, not elsewhere classified
Current SymbolNASDAQ:BXRX



Sales & Book Value

Annual SalesN/A



Market Cap$79.41 million
Next Earnings Date8/14/2020 (Estimated)
OptionableNot Optionable

Receive BXRX News and Ratings via Email

Sign-up to receive the latest news and ratings for BXRX and its competitors with MarketBeat's FREE daily newsletter.

Baudax Bio (NASDAQ:BXRX) Frequently Asked Questions

How has Baudax Bio's stock been impacted by COVID-19 (Coronavirus)?

Baudax Bio's stock was trading at $4.94 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BXRX stock has decreased by 8.5% and is now trading at $4.52. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Baudax Bio?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Baudax Bio in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Baudax Bio.

When is Baudax Bio's next earnings date?

Baudax Bio is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for Baudax Bio.

How were Baudax Bio's earnings last quarter?

Baudax Bio (NASDAQ:BXRX) announced its quarterly earnings results on Friday, May, 8th. The company reported ($4.03) earnings per share for the quarter, missing the consensus estimate of ($0.91) by $3.12. View Baudax Bio's earnings history.

What price target have analysts set for BXRX?

4 analysts have issued twelve-month price targets for Baudax Bio's shares. Their forecasts range from $12.00 to $14.00. On average, they anticipate Baudax Bio's share price to reach $13.00 in the next year. This suggests a possible upside of 187.6% from the stock's current price. View analysts' price targets for Baudax Bio.

Has Baudax Bio been receiving favorable news coverage?

Headlines about BXRX stock have been trending positive recently, InfoTrie reports. The research firm identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Baudax Bio earned a news sentiment score of 2.3 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days. View the latest news aboutBaudax Bio.

Are investors shorting Baudax Bio?

Baudax Bio saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 1,900,000 shares, an increase of 214.6% from the April 30th total of 604,000 shares. Based on an average daily trading volume, of 855,100 shares, the days-to-cover ratio is presently 2.2 days. Approximately 10.9% of the company's shares are sold short. View Baudax Bio's Current Options Chain.

Who are some of Baudax Bio's key competitors?

What other stocks do shareholders of Baudax Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Baudax Bio investors own include Gilead Sciences (GILD), ADMA Biologics (ADMA), Clovis Oncology (CLVS), Johnson & Johnson (JNJ), Micron Technology (MU), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), Adobe (ADBE), Amarin (AMRN) and Crispr Therapeutics (CRSP).

Who are Baudax Bio's key executives?

Baudax Bio's management team includes the following people:
  • Dr. Geraldine A. Henwood, Pres, CEO & Director (Age 68, Pay $48.37k)
  • Mr. Ryan D. Lake, CFO & Treasurer (Age 43, Pay $29.44k)
  • Dr. Stewart McCallum, Chief Medical Officer (Age 54)
  • Mr. John Harlow, Chief Commercial Officer (Age 44)
  • Mr. Randall J. Mack, Sr. VP of Devel. (Age 55)

What is Baudax Bio's stock symbol?

Baudax Bio trades on the NASDAQ under the ticker symbol "BXRX."

How do I buy shares of Baudax Bio?

Shares of BXRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Baudax Bio's stock price today?

One share of BXRX stock can currently be purchased for approximately $4.52.

How big of a company is Baudax Bio?

Baudax Bio has a market capitalization of $79.41 million. Baudax Bio employs 24 workers across the globe.

How can I contact Baudax Bio?

Baudax Bio's mailing address is 490 LAPP ROAD, MALVERN PA, 19355. The company can be reached via phone at 484-395-2470.

This page was last updated on 5/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.